Abstract: Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) is associated with significant mortality and morbidity. Case fatalities are often associated with severe neurological involvement in children and advanced age in adults but specific treatment is currently unavailable. Plasma exchange (PE) could theoretically enable removal of Shiga toxins, pro-inflammatory cytokines, and prothrombotic factors and has been used in deteriorating patients with STEC-HUS but the efficacy remains uncertain. In order to assess efficacy of PE in STEC-HUS, a literature review was performed. PubMed, Web of Science, Embase, and LiLACS were searched for reports describing the outcomes of patients with STEC-HUS treated with PE and 16 reports were included. Reports ranged from case reports to cohort studies and one case-control study with the largest study population coming from the 2011 German STEC-HUS outbreak. Outcomes were variable but seemed to point towards lower case fatality rates in the elderly and improved outcomes in children with STEC-HUS, treated with PE early in the course. However studies were mostly of low quality with risk of observation bias and confounding. Currently no definitive answers concerning the efficacy of PE in STEC-HUS can be given, highlighting the need for well performed randomized controlled trials.
Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) is a common cause of acute kidney injury (AKI) in children and associated with significant morbidity and mortality (1, 2) . People of all ages can develop HUS due to Enterohemorrhagic E. coli (EHEC) infection but children (≤ 5 years) and the elderly (> 60 years) are particularly vulnerable (2) (3) (4) . Extra-renal complications e.g. neurological involvement, pancreatitis, pulmonary hemorrhage, severe anemia and hemodynamic instability are also frequently seen. The case fatality rate is 3-5% in children and young adults while in the elderly much higher fatality rates (up to 30% or higher) have been observed (3, 4) . Treatment is supportive with measures such as fluid restriction, diuretics, antihypertensives, and renal replacement therapy. No specific treatment aimed at the primary inflammatory process is currently available. Plasma exchange (PE) has been used as a last-ditch effort to reverse the trend in a deteriorating patient with STEC-HUS but the efficacy remains uncertain (5, 6) . Conflicting reports have been published (7, 8) and we conducted this review to provide an overview of currently available outcomes of PE in STEC-HUS in order to assess its efficacy.
PLASMA EXCHANGE AND STEC-HUS
Plasma exchange removes large-molecular-weight substances, for example, harmful antibodies from the plasma. Typically, 30-40 mL/kg of plasma (1-1.5 plasma volumes) is removed at each procedure and replaced with either fresh frozen plasma or IV albumin solutions (albumin 4.5% or 5%) (9) . A one plasma volume exchange removes about 66% of an intravascular constituent and a two plasma volume exchange removes approximately 85% (9) . Ideal characteristics of molecules to be removed are (10):
• an identified toxic or etiologic agent • high molecular mass (≥15 000 D)
• slow rate of formation • low turnover • low volume of distribution Shiga toxin (Stx) produced by EHEC plays a major role in the development of STEC-HUS (2, 6, 11) and is composed of two major subunits, designated A and B with respective molecular weights of 32 225D and 7691D (6, 11, 12) . The B subunit forms a pentamer that binds to globotriaosylceramide-3 (Gb3) and this specificity determines where Shiga toxin mediates its pathologic effects (1) . Two types of Shiga toxins exist (e.g. Stx 1 and Stx 2) which display 57% and 60% nucleotide sequence homology in the A and B subunits, respectively (6, 11) . Both types are associated with HUS development but Shiga toxin 2 is more closely associated with human disease (6, 11) . Following ingestion, EHEC cause infection of the gastrointestinal tract in humans and destroy microvilli of the brush border of the large intestine inducing (hemorrhagic) colitis (6, 11) . Stx produced by these bacteria cross the gastrointestinal epithelium and enter the circulation after which they presumably bind to polymorphonuclear leukocytes (PMN) (5, 6) . Shiga toxins are then transported via the bloodstream and after detachment from PMN bind to organs and cells expressing Gb3, a glycosphingolipid (e.g. glomerular endothelial cells, kidney, brain, liver, pancreas, heart (6, 11) . Stx, via a complex pathway, induces an inflammatory cascade responsible for development of the thrombotic microangiopathy (TMA) and tissue inflammation characteristic of HUS (6, 11) .
In theory PE would be ideal to remove Stx from the circulation thereby limiting and/or preventing endothelial damage and tissue inflammation (6, 12, 13) . In addition it is also postulated to remove pro-inflammatory, prothrombotic factors and Shiga toxin-bound antibodies thereby limiting the inflammatory response (6) . A study by Lee et al. showed that Stx2 upregulated the expression of proinflammatory cytokines (e.g. TNF, PDGF) and fibrosis prone growth factors and suggested that the inhibition of these cytokines may limit endothelial injury (14) . PE could potentially also inhibit prothrombotic processes and limit TMA by providing fresh plasma from healthy individuals. A study by Remuzzi et al. (15) in adult patients with STEC-HUS showed the absence of the expected increased secretion of prostaglandin I2 (PGI2, prostacylin). PGI2 (secreted by endothelial cells) inhibits platelet activation, causes vasodilatation and has anti-inflammatory effects and the potential lack of a plasma factor inducing its secretion in STEC-HUS fueled the conception that plasma infusions could be efficacious in STEC-HUS (15) . Even though efficacy of plasma infusion in STEC-HUS could not be established in a randomized study performed by the same research group (16) , plasma infusions are still administered by some clinicians in an attempt to ameliorate the course of STEC-HUS (17) .
Plasma infusions and PE have been efficacious in the treatment of atypical HUS by providing lacking complement inhibiting factors (18) . Increasing evidence shows that heightened activity of the alternative pathway of the complement system is also present in STEC-HUS (19) (20) (21) . Removal of activated complement factors and providing complement inhibitors through plasma exchange could in theory also be beneficial in these patients.
METHODS
We searched the databases PubMed, LiLACS, Embase and Web of Science with relevant medical subject headings. We also selected additional references through bibliographies from identified articles. We restricted the search to articles in English and French and articles which were published after 1990. The decision to exclude reports published before 1990 was made in light of difficulties assessing full-text articles which often could not be located online (Fig. 1) .
Key words aimed at identifying studies describing plasma exchange prescribed for patients with STEC-HUS were used (e.g. diarrhea-associated hemolytic uremic syndrome, plasma exchange, plasmapheresis).
We identified and selected 16 reports (Table 1 ) describing outcomes of plasma exchange in STEC-HUS, ranging from case reports to cohort studies and one case-control study. One study (35) was excluded since in addition to PE, all patients had received eculizumab. The efficacy of eculizumab has currently not been disproven (36) and we believe that including this study could present a source of confounding.
Data was extracted from these studies but no meta-analysis was performed because of the lack of homogeneity of the studies and missing data.
This review was performed in accordance with the Declaration of Helsinki. Table 1 with outcome details presented in Table 2 .
RESULTS

An overview of included reports is presented in
Dundas et al. reported the outcomes of an EHEC outbreak in central Scotland in 1996 resulting in 120 EHEC infections, 34 STEC-HUS cases and 16 deaths (22, 23) . A total of 22 adults (22/34, 64.7%) developed HUS. Plasma exchange was administered to 16 adults with a mean age of 71 years of which five (31.3%) died (22, 23) . Authors compared results to those of an outbreak in 1987 in a Scottish retirement home during which 11 of 12 elderly residents (mean age 83 years) died After appearance of neurological symptoms.
-, unknown or not presented; N, number of patients receiving PE; PE, plasma exchange; sCreat., serum creatinine; NS, non-significant; S, significant.
(91.6%) (37) . According to authors the unavailability of PE was the only difference in management between these outbreaks and they concluded that PE was a promising treatment option in the elderly with STEC-HUS (23 (31) . At one-year follow-up median value of plasma creatinine was non-significantly lower in the PE+ group (0.7 mg/dL vs. 0.9 mg/dL) while median value of creatinine clearance was non-significantly higher in PE+ group (96 vs. 80 mL/min/1.73 m 2 ). In addition, creatinine clearances <60 mL/ min/1.73 m 2 (9/22) and end stage renal failure (3/22) were exclusively seen in the PE-group (31). Nakatani et al. described outcomes of three children immediately receiving PE after STEC-HUS diagnosis and before development of severe renal failure with complete resolution of symptoms (32) .
Reports by Nathanson et al. and Valles et al. (17, 33) described outcomes in children with severe neurological involvement and treated with PE, showing overall survival of 72.9% (27/37) patients. Loos et al. described pediatric outcomes of 17 children (16 of 17 with neurological involvement) treated with PE out of 90 children with STEC-HUS. Even though overall outcome (case fatality 1.1%) was good, no significant difference was seen compared to those children treated with basic supportive care (34) .
All reports were assessed via the GRADE system (Grading of Recommendations, Assessment, Development and Evaluations) and were almost all graded low quality evidence with high risk of selection and/or observation bias and confounding. One study (31) was graded as medium quality evidence in light of the presence of a control group and the long term follow-up.
DISCUSSION
The first reports describing outcomes from patients with Shiga toxin-associated hemolytic uremic syndrome treated with plasma exchange, date from the 1980's with early results pointing towards potential efficacy of this treatment option (38) (39) (40) . Currently, more than 30 years later, no randomized controlled trial (RCT) evaluating the efficacy of plasma exchange (PE) in STEC-HUS has been performed and the use of PE for this condition remains controversial (5, 6) . Underlying reasons for the lack of RCT's are obviously related to the relatively low incidence of this condition and the financial and technical burden this treatment option poses in low resource settings.
Both reports by Colic et al. (7) and Dundas et al. (23) suggest significantly improved outcomes in adults >60 years treated with PE early in the course of the disease. Colic et al. (7) described 5 adults (median age 62 years) with STEC-HUS and neurological involvement who fully recovered after receiving plasma exchange shortly after STEC-HUS diagnosis. Dundas et al. (23) showed a lower case fatality rate in elderly patients (mean age 71 years) when compared to historic controls (31.2% vs. 91.6%) with STEC-HUS treated without PE (22, 23, 37) . Case fatality rates in the elderly are disproportionately high and these reports could provide important information pointing to the efficacy of PE. However both studies lacked control groups, were prone to observation bias and selection bias, and had a limited number of included patients.
The largest adult population studied came from reports from the catastrophic German STEC-HUS outbreak in 2011 during which 845 cases of STEC-HUS were noted (8, 31) . Authors of these reports concluded that since outcomes from patients treated with PE did not significantly differ from those treated with basic supportive care, PE was unlikely to be beneficial in STEC-HUS (8, 31) . It is worth pointing out that in both trials patients treated with PE were more severely affected than those receiving basic supportive therapy. In addition, neurological involvement was an important indication for prescribing PE and case fatalities in STEC-HUS are often associated with this complication (17, 41) . In both trials case fatality rates were lower in patients receiving PE compared to those receiving basic supportive care. When combining data from these two studies and comparing case fatalities in patients who received PE (17/492, 3%) to those treated with basic supportive care (10/104, 9.6%) a significantly higher case fatality rate (P = 0.006) is seen in the basic supportive care group. Since elderly patients are most prone to negative outcomes and > 70% of case fatalities in these studies was seen in patients >60 years, these results might point to potential efficacy of PE in reducing case fatalities in STEC-HUS, especially in the elderly.
However, the data by Menne et al. (8) and Kielstein et al. (27) probably overlap since the Kielstein data are from a nationwide ad hoc online registry while the Menne data were retrieved in detail by collecting data and downloading laboratory data in many centers that treated STEC-HUS patients.
Case reports show varying results in adults receiving PE but since the high likelihood of selection and /or publication bias, drawing conclusions based on this data is not appropriate. For example in the case report by Matano et al. (29) outcomes of just four patients out of 163 are presented, clearly indicating selection bias which renders drawing conclusions based on this data impossible.
The study by Gianviti et al. (31) probably provides the highest quality evidence concerning the efficacy of PE in pediatric STEC-HUS. In this casecontrol study, 11 children at risk for poor outcome showed non-significant better long term renal outcome compared to those treated with supportive therapy with patients developing CKD stage 3 or worse limited to the PE-group. Since the study by Gianviti et al. (31) , no such trials have been undertaken. The largest pediatric population studied emanates from the German outbreak (34) and showed no significant difference in outcomes in those treated with PE compared to those with supportive therapy. However it should be emphasized once again that PE was given to the most severely affected with 16 of 17 patients having neurological involvement. No children treated with PE died even though neurological involvement in children with STEC-HUS is the most common cause of fatalities (1-4). Nathanson et al. reported 25 of 52 patients with severe neurological involvement treated with PE. From these 25 children, 11 received PE within the first 24 h but outcomes did not differ compared to children with severe neurological involvement not receiving PE or to children receiving PE later in the course. Authors conclude that their study could not exclude the benefits of plasma exchange since complications might have been worse if PE had not been given (17) . In the trial by Valles et al., 12 patients with severe neurological involvement and hemodynamic instability received PE (5 days), plasma infusions and methyl prednisolone (10 mg/ kg/d for 3 days) (33) . Nine patients survived of which two developed neurological sequelae and one developed CKD. Efficacy of PE in this study was difficult to assess in light of the multiple therapies administered and lack of a control group.
We believe that even though current evidence is very limited, there are indications that PE may be beneficial in patients with STEC-HUS > 60 years of age in reducing case fatalities and improving outcomes (7, 8, 23, 31) . If PE is efficacious in the elderly, it would be difficult to assume the opposite being the case in children or adults <60 years. In addition, results from several pediatric trials (31, 32, 34) seem to provide indications of its efficacy.
However most children with STEC-HUS will improve with basic supportive therapy without the need for PE (34) . Case fatalities in children are often associated to neurological involvement and early predictors of poor outcome include prolonged anuria, hemoconcentration, and hyponatremia (2, 3, 5, 42) .
Shiga toxins have shown to be present in patient serum in the first 24-48 h of infection with EHEC with concentrations quickly diminishing thereafter suggesting that with regard to removal of these toxins, PE would be less or not efficacious if started late in the course (43, 44) .
CONCLUSION
Limited and weak current evidence suggests potential efficacy of early plasma exchange in reducing case fatality rates in elderly patients with STEC-HUS and potentially improving outcomes in children with severe involvement. Early institution of PE would theoretically increase the likelihood of significant removal of Shiga toxins but could also aid in disease modifying effects related to, for example, removal of pro-inflammatory cytokines, prothrombotic factors and limiting complement activation. Our conclusion potentially adds to the 2016 guidelines on the use of therapeutic apheresis from the American Society for Apheresis (47) which categorized Shiga toxin-mediated HUS without neurological complications as a Category 3 or 4 indication implying that published evidence demonstrates or suggests apheresis to be ineffective or harmful (47) . Our review however adds important information that might be overlooked if all STEC-HUS cases were considered to be "equal." In that case it is quite understandable that the conclusion would be that PE is ineffective since most cases of STEC-HUS improve and show full recovery with supportive treatment. However, thoroughly evaluating pediatric and adult studies and, for example, identifying the elderly as a high-risk group, has led us to conclude that PE might be efficacious in selected cases. Immunoadsorptive therapy with IgG depletion used during the 2011 German outbreak for therapy resistant cases with late neurological complications resulted in improved outcomes but very limited additional information concerning this treatment modality is presented in current literature (45, 48) . This could also be said for corticosteroids as currently evidence does not support efficacy of corticosteroids in SEC-HUS. Again here, the evidence is very limited and we could only retrieve one randomized trial evaluating its usefulness (45, 46) . Based on current evidence or lack thereof we do believe that currently no definite recommendations concerning the use of plasma exchange in Shiga toxin-associated hemolytic uremic syndrome can be made and that higher quality evidence is required.
In adults >60 years with STEC-HUS we believe that in light of high case fatality rates and potential efficacy of PE, there is a case to be made for early institution of PE. In children and adults<60 years there might be a rationale to limit the indication for PE to those at risk for poor outcome. There is an obvious need for high quality, controlled randomized trials to provide definitive answers.
